DermaVue SuperHuman · Physician-Reviewed
Ozempic, Mounjaro and eyesight: the numbers explained
A rare eye problem has been reported with these weight-loss and diabetes medicines. The tables below show how often it happened in a large research review, in plain numbers.
These medicines are linked to a rare eye condition called NAION. It can cause sudden vision loss in one eye. A link is not the same as proof of cause.
In a large research review it happened to very few people. The rate was a little higher in the medicine group than the comparison group. Most people never have any eye problem.
If you suddenly lose vision or your eyesight quickly worsens, seek eye care immediately.
What did the FDA review find?
On 9 November 2026 the US FDA reviewed data from 126 clinical trials. More than 134,000 people took part. The table shows the raw counts.
| In the studies | People taking the medicines studied | People given a dummy treatment or other diabetes medicines |
|---|---|---|
| People included | 78,217 | 56,036 |
| Probable cases of the eye condition NAION | 10 | 5 |
These groups were followed for different lengths of time. Researchers accounted for this when comparing the rates.
Allowing for the time people were followed
| Group | Cases per 1 lakh (100,000) patient-years |
|---|---|
| Medicines studied | 6.4 |
| Comparison treatments | 3.8 |
One lakh patient-years means the same total follow-up as one lakh people followed for one year.
This eye problem was rare in both groups. The medicine group had a higher observed rate. These combined results do not give the exact risk for each brand.
Source: US FDA Drug Safety Communication, 9 November 2026. The FDA added this to the medicines' warnings after the review. It states that a cause has not been proven.
Common questions, short answers
| Question | Answer |
|---|---|
| Is this eye problem common? | It is rare. In a large review, about 6 in 1 lakh (100,000) people a year on the medicines had it, against about 4 in 1 lakh not on them. |
| Does this mean everyone taking these medicines is at risk? | No. Most people never have this eye problem. The numbers were small in both the medicine group and the comparison group. |
| Is the risk identical for Ozempic and Mounjaro? | We cannot say. The clearest signal is for semaglutide (Ozempic, Wegovy, Rybelsus). The combined data does not give a reliable figure for each separate brand. |
| What should I discuss with my doctor? | Your eye and general health history, any past eye problems, and which medicine you take. Individual advice depends on these and the specific medicine. |
| What if I notice a change in my eyesight? | A sudden loss or dimming of vision in one eye needs eye care the same day. A gradual change should be checked and discussed with your doctor, not managed on your own. |
Individual treatment decisions depend on your health history and the specific medicine. Your treating doctor gives advice for your case.
Which medicines are we talking about?
These are called GLP-1 medicines. They are used for weight loss and for type 2 diabetes. Here are the names people recognise.
| Name patients recognise | Medicine name |
|---|---|
| Ozempic, Wegovy, Rybelsus | Semaglutide |
| Mounjaro | Tirzepatide |
These are examples covered by the discussion. The pooled research included several medicines in this group. The clearest signal was for semaglutide. There is no reliable figure for tirzepatide (Mounjaro) on its own, so we do not quote one.
Rare serious effects are not unique to these medicines
GLP-1 medicines are in the news, so this risk feels new and large. In fact, many familiar everyday medicines carry an uncommon but serious effect that most people never have. One of them is linked to the same eye condition, NAION.
| Everyday medicine | Common use | A rare but serious effect |
|---|---|---|
| Sildenafil, tadalafil (Viagra, Cialis) | Erectile problems, some blood pressure conditions | NAION, the same optic-nerve condition, is listed on the label |
| Ciprofloxacin, levofloxacin (fluoroquinolone antibiotics) | Serious infections | Tendon rupture and, rarely, a tear in the main artery (a boxed warning) |
| Amoxicillin, co-amoxiclav (Augmentin) | Common antibiotic | Severe allergic reaction; rare liver injury; seizures at very high doses or in kidney disease |
| Combined contraceptive pill | Contraception | Blood clots in the legs or lungs |
| Paracetamol (acetaminophen) | Pain and fever | Serious liver damage in overdose |
| Ibuprofen and similar painkillers (NSAIDs) | Pain and inflammation | Stomach bleeding and strain on the kidneys |
This table is for perspective, not alarm. It does not mean any of these will happen to you. It shows that a rare, serious effect sitting in a medicine's label is normal, and is a reason to use any medicine with a doctor, not a reason to panic about one.
Read the research
The detail below is for readers who want it. The main points are in the tables above.
The exact numbers and how they were measured
The FDA pooled 126 randomised controlled trials, covering 134,253 people (78,217 on a GLP-1 medicine, 56,036 on a comparison treatment). Follow-up added up to 288,879 patient-years. There were 15 probable NAION cases: 10 in the GLP-1 group, 5 in the comparison group.
| What | Figure |
|---|---|
| Rate on a GLP-1 medicine | 6.4 per 100,000 patient-years |
| Rate on comparison treatment | 3.8 per 100,000 patient-years |
| NAION in adults over 50 without these medicines | About 2 to 10 per 100,000 per year |
The difference seen in this analysis was small, and only 15 people were affected in total. With numbers this small, the true figure could be higher or lower. The FDA also checked a large real-world database (Sentinel). The signal was just significant against one group of diabetes drugs and not significant against another.
Does the risk differ between medicines?
The combined data cannot give a reliable figure for each separate brand. The clearest signal is for semaglutide (Ozempic, Wegovy, Rybelsus). That is the medicine the first 2024 study and the European review looked at. The direct evidence for tirzepatide (Mounjaro) on its own is limited and points in different directions, so no one can give a reliable Mounjaro-only number. We do not claim Mounjaro is safer or riskier than the others.
What have Europe and India said?
Europe: in 2025 the European Medicines Agency's safety committee concluded that NAION is a "very rare" side effect of semaglutide medicines, meaning it may affect up to 1 in 10,000 people. The product information for Ozempic, Wegovy and Rybelsus was updated to include it. This was specific to semaglutide, not the whole group.
United States: the FDA action of 9 November 2026 is a change to the Warnings and Precautions part of the label. It applies to the whole GLP-1 group. It is not a ban and not a boxed warning. The FDA states that a cause has not been proven.
India: we have not found a NAION advisory from India's drug regulator (CDSCO) so far. Indian physicians have responded to the global data by advising patients not to stop these medicines on their own. There is no India-specific study of NAION with these medicines, so the India-specific risk is simply not known. We apply the international evidence carefully and watch each patient as an individual.
What is NAION, and can it be reversed?
NAION is short for non-arteritic anterior ischemic optic neuropathy. In plain words, it is like a stroke of the optic nerve, the cable that carries pictures from the eye to the brain. The blood supply to the front of that nerve drops, and vision in that eye is lost suddenly, usually without pain, often noticed on waking.
There is no proven treatment that reverses it. Some people get part of their vision back on their own over months. Some loss can stay. People who already have a crowded optic disc, obstructive sleep apnea, diabetes, high blood pressure, or a previous NAION in one eye start with a higher baseline chance, with or without any medicine.
Can these medicines prevent or guarantee against NAION?
There is no proven way to prevent NAION, and no test reliably predicts who will get it. Managing general risk factors, such as treating sleep apnea and controlling blood pressure, is sensible for overall health, but it is not proven to stop NAION. A medical review does not remove the risk. What it can do is take your own history into account, explain the warning signs, and arrange fast eye care if symptoms appear.
A short note about eye symptoms
A new change in your eyesight can have many causes. Some settle, some do not. The safest approach is simple.
If you suddenly lose vision, or your eyesight quickly worsens, seek eye care immediately. Go to an eye hospital or emergency eye service the same day. Do not wait for a routine appointment.
For a gradual or mild change, book an eye check and discuss it with the doctor who prescribes your medicine. Do not start or stop treatment on your own because of a vision change. Let your doctor weigh it with you.
Our WhatsApp and booking replies are for routine questions. They are not an emergency service and must not delay urgent eye care. Please do not use WhatsApp to report sudden vision loss.
Have questions about your treatment?
Speak with the SuperHuman team. We can review your treatment and your personal risk factors, and help you plan the next step. The first review is available as a video consultation, so you can talk to a physician from home.
This eye problem is rare. The research showed a higher rate in the medicine group, but a cause is not proven, and most people are unaffected. The clearest signal is for semaglutide, and there is no reliable Mounjaro-only figure. Know the one red flag, sudden vision loss in one eye, and get same-day eye care if it happens. For anything else, do not change your treatment alone; talk to your doctor.
Sources
The evidence this page is built on
- US FDA. Drug Safety Communication: safety labeling changes for GLP-1 receptor agonists due to potential increased risk of NAION. 9 November 2026. fda.gov
- Hathaway JT, et al. Risk of NAION in patients prescribed semaglutide. JAMA Ophthalmology. 2024;142(8). jamanetwork.com
- European Medicines Agency (PRAC). NAION a very rare side effect of semaglutide medicines. June 2025. ema.europa.eu
- US FDA. Sildenafil (PDE5 inhibitor) labeling, NAION warning (comparison example).
- Background NAION incidence and clinical course: peer-reviewed reviews of non-arteritic anterior ischemic optic neuropathy.
Figures are quoted as published. Where evidence is limited or mixed (for example, tirzepatide-specific data and India-specific data), the page says so rather than fill the gap.
DermaVue provides physician-supervised medical weight-management services. This page is general information, not a substitute for individual medical advice, diagnosis, or an eye examination. It does not promise any outcome and does not claim to prevent NAION or remove medication risk. For sudden vision changes, seek urgent eye care.
Visit Any of Our 7 Clinics
Or book a teleconsultation from anywhere in India